Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Health Monitor Liechtenstein.
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
GlobeNewswire, Inc.
·
June 20, 2025
VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First...
Liechtenstein Reaffirms Global Leadership in Stability and Philanthropy
EIN Presswire
·
June 9, 2025
LONDON, UNITED KINGDOM, June 9, 2025 /EINPresswire.com/ -- The Principality of Liechtenstein continues to demonstrate its exceptional standing on the global stage, with two recent developments underscoring its strength in both financial...
Dental Implants Market worth US$18.79 billion by 2030 with 8.4% CAGR | MarketsandMarkets™.
GlobeNewswire, Inc.
·
June 19, 2025
Delray Beach, FL, June 19, 2025 (GLOBE NEWSWIRE) -- The global dental implants market, valued at US$11.61 billion in 2024, stood at US$12.57 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in...
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
GlobeNewswire, Inc.
·
April 15, 2025
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*)...
4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion
GlobeNewswire, Inc.
·
March 17, 2025
Press Release 4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion Araris will receive USD 400 million upfront, with the potential for additional near-term and long-term milestone payments...
OSCE workshop fosters regional dialogue on climate change, human mobility, and security in South-Eastern Europe
Organization for Security and Co-operation in Europe
·
June 17, 2025
On 3 June, the Office of the Co-ordinator of OSCE Economic and Environmental Activities (OCEEA) hosted a regional workshop in Sarajevo, Bosnia and Herzegovina, bringing together over 50 experts, officials, civil society representatives, and...
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire, Inc.
·
June 6, 2025
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an orally administered treatment for DMD in patients 6 years and older who are able to walk The...
Working Visit of His Serene Highness Hereditary Prince Alois Philipp Maria of the Principality of Liechtenstein to Singapore, 1 to 4 November 2024
Singapore Ministry of Foreign Affairs
·
October 31, 2024
His Serene Highness Hereditary Prince Alois Philipp Maria of the Principality of Liechtenstein will make a working visit to Singapore from 1 November to 4 November 2024. During the visit, HSH Hereditary Prince Alois will meet President Tharman...
Increasing Oral Healthcare Awareness to Propel Dental Equipment Market Growth at USD 10.90 Billion by 2031 |SkyQuest Technology
GlobeNewswire, Inc.
·
October 18, 2024
Westford, USA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dental Equipment Market size was valued at USD 6.79 billion in 2023 to USD 10.90 billion by 2031, growing at a CAGR of 6.10% during the forecast period (2024-2031). The tools that are utilized for...
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire, Inc.
·
May 23, 2025
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing...
Guide to Optimal Nutrition for Vegans
College of Naturopathic Medicine
·
June 21, 2024
Country(Required)Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin...
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire, Inc.
·
April 28, 2025
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28,...
Ligand Reports First Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
May 8, 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
GlobeNewswire, Inc.
·
April 28, 2025
VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission...
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
GlobeNewswire, Inc.
·
April 16, 2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today...
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
GlobeNewswire, Inc.
·
March 20, 2025
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG)...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire, Inc.
·
February 28, 2025
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal...
Fish Fund Steering Committee advances work on Call for Proposals, welcomes new members
World Trade Organization
·
May 20, 2025
The agreement on next steps brings the Steering Committee closer to opening its first Call for Proposals. The Fund will receive funding requests for project grants that will support developing and least developed country (LDC) members to implement...
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
GlobeNewswire, Inc.
·
March 29, 2025
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization...
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire, Inc.
·
February 27, 2025
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30...